DI
CPRX

Disciplined Investments’s Catalyst Pharmaceutical CPRX Stock Holding History

Disciplined Investments’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3
Closed -$40 – 416
2023
Q2 		$40 Buy
3
+2
+200% +$29 ﹤0.01% 1667
2023
Q1 		$17 Buy
+1
New +$16 ﹤0.01% 1674

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Disciplined Investments's CPRX Position: Q3 2023 in Review

Disciplined Investments sold out of Catalyst Pharmaceutical (CPRX) in Q3 2023, closing a stake of 3 shares — an estimated $40 sold.

Disciplined Investments first reported a position in CPRX in Q1 2023 and held it in 2 quarters. The position peaked at $40 in Q2 2023. 255 funds tracked by Wall St. Rank hold CPRX as of Q3 2023.

  • Disciplined Investments reported no remaining Catalyst Pharmaceutical position as of Q3 2023 after selling out during the quarter.
  • Disciplined Investments sold 3 Catalyst Pharmaceutical shares in Q3 2023, an estimated $40.
  • Disciplined Investments first reported a position in Catalyst Pharmaceutical in Q1 2023 and held it in 2 quarters.
  • Disciplined Investments's Catalyst Pharmaceutical position peaked at $40 in Q2 2023.
  • 255 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2023.

Based on Disciplined Investments's 13F filing for Q3 2023, filed 14 Nov 2023.